basys

basys.ai is a health technology company that leverages generative artificial intelligence to transform the management of metabolic health, specifically targeting diabetes and obesity. Founded by alumni from Harvard and MIT, the company provides a platform for health plans and providers to predict clinical outcomes and personalize treatment pathways. Their technology utilizes deep learning to analyze longitudinal patient data, aiming to improve patient outcomes while reducing the cost of care. The company's primary focus is on cardiometabolic health, offering tools for prior authorization automation and clinical decision support. By integrating with existing healthcare workflows, basys.ai helps stakeholders manage the increasing demand and cost associated with GLP-1 medications. The company is currently part of the Mayo Clinic Platform_Accelerate program and maintains a presence in the Lilly Gateway Labs.